Biogen publishes Alzheimer’s drug data in low-ranking journal
The disease-modifying therapy, which was granted accelerated approval in the US last year, is currently under consideration by the TGA
The biotechnology company behind the troubled Alzheimer’s drug aducanumab has been embroiled in a fresh round of controversy following the long-awaited release of results from two pivotal studies.
Last week, the US-based company Biogen published data from the phase III trials in a lesser-known medical journal — The Journal of Prevention of Alzheimer’s Disease — whose editor-in-chief Dr Paul Aisen was a co-author of the studies.
